SCHEDULE: Norwest Venture Partners' MBX Biosciences Stake Dips Below 5%

Norwest Venture Partners and its affiliates reported a decrease in their beneficial ownership of MBX Biosciences common stock to 4.8% following the company's recent public offering.

Summary

• Norwest Venture Partners XVI, LP and its affiliated entities (Genesis VC Partners XVI, LLC, NVP Associates, LLC, Jeffrey Crowe, Jon Erik Kossow, and Tiba Aynechi) filed an Amendment No. 1 to their Schedule 13D.
• The amendment reports a dilution in beneficial ownership of MBX Biosciences, Inc. common stock, not an acquisition or disposition of securities by the reporting persons.
• This dilution resulted from MBX Biosciences' underwritten public offering, which closed on September 26, 2025, increasing the total number of outstanding shares.
• Norwest Venture Partners XVI, LP and its related entities now beneficially own 2,136,335 shares, representing 4.8% of the class.
• Tiba Aynechi, an officer of NVP Associates and a director of MBX Biosciences, beneficially owns 2,140,989 shares (including 4,654 exercisable options), also representing 4.8% of the class.
• The reporting persons ceased to be beneficial owners of more than five percent of MBX Biosciences common stock on September 26, 2025.

Sentiment

Score: 5

Explanation: The filing is neutral from the perspective of the reporting persons, as it reports a passive dilution due to an issuer's capital raise, which is a standard event. For the issuer, a successful capital raise is generally positive, but the filing doesn't provide details on the offering's success or terms.

Positives

• The public offering by MBX Biosciences, Inc. likely raised capital for the company, which can support its operations and strategic initiatives.

Negatives

• The reporting persons' percentage ownership in MBX Biosciences, Inc. has been diluted, reducing their proportional influence and share of future profits.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from MBX Biosciences, Inc. It primarily reports a historical change in ownership percentage.

Industry Context

This filing reflects a common occurrence in the biotech or growth-stage company lifecycle where early investors' stakes are diluted as the company raises additional capital through public offerings to fund research, development, or commercialization. The public offering itself suggests MBX Biosciences is actively seeking to finance its operations and growth.

Related Party Transactions

• Tiba Aynechi is identified as an officer of NVP Associates, LLC (an affiliate of Norwest Venture Partners) and a director of MBX Biosciences, Inc., establishing a related party relationship. Her beneficial ownership is disclosed.

Stakeholder Impact

• Shareholders: Existing shareholders of MBX Biosciences, Inc. experienced dilution of their ownership percentage due to the public offering.
• Reporting Persons (Norwest Group): Their percentage ownership decreased below 5%, potentially reducing their influence as a major shareholder.
• MBX Biosciences, Inc. (Issuer): The public offering likely provided additional capital for operations and growth.

Key Dates

Recommendation

This filing primarily reports a passive dilution of a significant investor's stake due to a public offering by the issuer. It does not provide new information about the issuer's financial performance, strategic direction, or operational results that would warrant a change in investment thesis. The public offering itself, while dilutive, is a common capital-raising mechanism for growth companies. Investors should hold and await further operational updates from MBX Biosciences, Inc.

Keywords

MBX Biosciences, Norwest Venture Partners, Schedule 13D/A, Beneficial Ownership, Public Offering, Equity Dilution, Venture Capital, SEC Filing